Transparency

Every state in the nation has proposed bills to limit pharmaceutical drug prices and the pace of that legislative work increases each year. The usual responses from pharmaceutical manufacturers and their allies is to threaten to reduce their investments in new drug research and development and challenge the new state laws in federal court. In […]

Read More
  • Publications

    Navigating Legal Challenges to State Efforts to Control Drug Prices: Pharmacy Benefit Manager Regulation, Anti-Price-Gouging Laws, and Price Transparency

    States have passed an unprecedented number of laws addressing drug prices over the past few years and some have faced legal challenges. This NASHP legal brief explores those challenges and highlights how states can develop effective drug pricing policies to avoid legal challenges. The brief analyzes the arguments industry groups have made against pharmacy benefit manager regulations, […]

    Read More
  • State Health Policy Blog

    Implementing Rx Drug Transparency: States Are Shining a Light on High-Cost Drugs and their Impact on Premiums

    As health plans prepare to submit rate filings, a new report from Oregon’s Division of Financial Regulation’s Prescription Drug Price Transparency Program illuminates just how much prescription drug prices impact insurance premiums. To increase health care cost transparency, Oregon requires health insurance companies to report on the impact of prescription drug prices on insurance plan […]

    Read More
  • State Health Policy Blog

    NASHP Partners with Mathematica to Strengthen State Rx Transparency Laws

    The National Academy for State Health Policy (NASHP) is partnering with Mathematica Policy Research to help states increase transparency and accountability to address rising prescription drug prices. This state-directed partnership will support the alignment of data collection and enable cross-state analyses. Currently, California, Oregon, Nevada, Connecticut, and Vermont require manufacturers to report on price increases […]

    Read More
    November 20, 2018 | Filed under: Front Page, Rx, State Health Policy Blog, Transparency

  • State Health Policy Blog
    States Take Administrative Actions to Curb Medicaid Drug Costs

    States Take Administrative Actions to Curb Medicaid Drug Costs

    During the 2018 legislative session, 28 states passed 45 laws to curb the rising cost of prescription drugs. In addition to legislative solutions, states are taking administrative action to better manage state spending on Medicaid pharmacy benefits. Ohio, West Virginia, and Vermont offer examples of states taking innovative administrative approaches to rein in drug costs. […]

    Read More
  • NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP’s Center for State Rx Drug Pricing seeks a partner to provide technical and strategic expertise to help a workgroup of state officials from California, Nevada, Oregon, Connecticut, and Vermont implement their drug cost transparency laws and help Maine and New Hampshire develop transparency programs as mandated by recent legislation. This work will help all […]

    Read More
    September 18, 2018 | Filed under: Drug Pricing, Featured-Rx, Front Page, Front Page-Rx, Transparency

  • State Health Policy Blog
    Twenty-Eight States Passed 45 Bills to Curb Rising Rx Drug Costs in the Short 2018 Legislative Session

    Twenty-Eight States Passed 45 Bills to Curb Rising Rx Drug Costs in the Short 2018 Legislative Session

    *Updated Oct. 15, 2018 Despite a short legislative season, state lawmakers across the country introduced an unprecedented 174 bills to stem the rising cost of prescription drugs and have enacted 45 into law — with seven state legislatures still in session. Last year, state legislatures introduced 100 Rx cost control bills and passed 27. Register […]

    Read More
  • A Glossary of All Terms Pharma

    A Glossary of All Terms Pharma

    If you’re working to control the cost of prescription drugs, you need to know the lingo used by the pharmaceutical industry. Below is a glossary of terms commonly used by players in the drug research, regulation, manufacturing, distribution, and purchasing worlds. Drug Product Terms Brand product: Branded products are not generic drugs or products. A brand can be […]

    Read More
  • State Health Policy Blog
    States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing

    States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing

    Several states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. These laws are an important first step to shine a light on why drug prices are rapidly climbing. To address a problem, state health policymakers need to understand it, but transparency laws don’t yet give […]

    Read More
  • Publications
    Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation

    Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation

    As the number of state bills to rein in prescription drug prices grows beyond 150 nationwide in 2018, the first generation of several state laws passed last year are now before the courts. The pharmaceutical industry has consistently challenged drug cost transparency and price gouging legislation passed in 2017 in federal courts. How well these […]

    Read More